Articles On Amplia Therapeutics (ASX:ATX)

  ASX hits record high as Wall Street rallies Mining and tech sectors lead gains while banks also climb Myer shares drop 4pc after sales decline, Harvey Norman facing second class action   The ASX touched a record high just minutes into...

Melbourne-based Amplia Therapeutics (ASX: ATX) has been granted Fast Track Designation for its narmafotinib advanced pancreatic cancer treatment candidate by the US Food and Drug Administration (FDA). Narmafotinib is the company’s best-in-c...

Good morning, and welcome to Stockhead’s Top 10 at somewhere near 11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

ASX set to rise as US stocks hit new highs S&P 500 reaches record 39th high amid rate cut optimism Larry Ellison becomes second-richest person after Oracle surges 20pc this month   The ASX is set to extend gains when the market opens...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from James McDona...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Telix Pharmaceuticals (ASX:TLX) CEO and co-founder Dr Chris Behrenbruch is blunt about why some fund managers believe the ASX market darling is entering ‘overvalued’ territory. “The fundies probably hate [us] because they didn’t get their a...

The ASX200 made a small recovery today after the torrid start to the week, closing up a quarter of a per cent to about 7700 points. Real Estate made the biggest recovery, adding nearly 1.3%, followed by Utilities and Telecommunications –...

Amplia Therapeutics Ltd (ASX:ATX) says that a fourth patient enrolled in a trial testing the efficacy of narmafotinib to treat advanced pancreatic cancer has shown a confirmed partial response. This follows news last month – on July 25 –...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

ASX and regional markets are sharply lower after Wall St tech crunch All 11 local sectors hit, InfoTech smashed hardest on -2.7pc Tissue Repair leads small caps on happy TGA approval news   The benchmark has followed sharp falls across...

The S&P/ASX All Ordinaries Index (ASX: XAO) is down 1.25% on Thursday to 8,102.6 points following a Wall Street dive overnight. The S&P 500 Index (SP: .INX) fell 2.31%, and the Nasdaq Composite Index (NASDAQ: .IXIC) lost 3.64%...

The 2024 Bioshares Biotech Summit being held in Fremantle from July 12-13 Morgans says conference likely to attract institutional and high net worth WA investors  Day one focus on new opportunities, finding the next blockbuster drug and re...

Island Pharmaceuticals inks deal to develop a treatment for potentially deadly viruses like Ebola Amplia recruits key 26th patient in Phase 2a trial of new treatment for advanced pancreatic cancer  Melodiol Global Health records unaudited...

Drug developer Amplia Therapeutics Ltd (ASX:ATX) has announced the enrolment of 26 patients as part of its clinical trial – dubbed ‘ACCENT’ – to test the use of its drug narmafotinib in the treatment of advanced pancreatic cancer. The pa...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

For biotech investors, the news of an approval by the US FDA is a genuinely exciting milestone. The FDA is the ultimate gatekeeper for the US pharmaceutical market, which is by far the world’s largest. Approval from the FDA not only validat...

By Tim Boreham, Editor, The New Criterion ASX code: ((ATX)) Market cap: $17.93m Shares on issue: 271,609,233 Chief executive officer: Dr Chris Burns (co-founder) Board: Dr Warwick Tong (chair), Dr Burns, Dr Robert Peach, Jane Bell Financial...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Amplia Therapeutics (ASX:ATX) is progressing thee Phase 2a stage of the ACCENT trial involving its FAK-inhibitor narmafotinib in combination with gemcitabine and abraxane.

Amplia Therapeutics (ASX:ATX) has progressed its ACCENT trial to evaluate narmafotinib, a drug that treats solid tumours in advanced pancreatic cancer patients. The ACCENT trial, conducted in two stages, assesses the safety and efficacy...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Amplia reports positive data from pancreatic cancer trial Emyria was given endorsement by ethical committee for its TGA application MedAdvisor’s Q1 sales were up 27pc   Amplia reports promising data from pancreatic cancer trial Amplia The...

Amplia Therapeutics (ASX:ATX) receives $2.4 million from the government The money comes as part of a national research and development tax incentive The R&D work done relates to the company’s ongoing pancreatic cancer trial...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

HIGHLIGHTS Data from preclinical studies in ovarian cancer presented at premier international conference in Boston, USA.  Results indicate that Amplia’s proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Oncology radiology leader Telix Pharmaceuticals is taking on the US, Tim Boreham reports. By Tim Boreham ASX Code: ((TLX)) Share price: $11.26 Shares on issue: 318,808,268 Market cap: $3.58 billion Chief executive officer: Dr Christian Behr...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

HIGHLIGHTS Amplia’s highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer FOLFIRINOX is the most widely used treatment for pancreatic cancer patients...

Tissue Repairs and Radiopharm surge after US FDA meetings Avecho granted application approval by US Patent Office Amplia demonstrated efficacy of its pancreatic drug   Tissue Repair to progress to Phase 3 Wound healing specialist Tissue R...

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

Amplia Therapeutics (ASX:ATX) has received grant funding to undertake a research collaboration with Australia’s national science agency CSIRO to develop novel topical formulations of the company’s FAK inhibitors.

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

The ASX opened lower this morning, while majority of the sectors dragged. Finance and communications fell 0.5 per cent, while healthcare also took a hit – down 0.13 per cent. However, Amplia Therapeutics (ATX) appeared immune to the...

Amplia Therapeutics (ATX) receives grant funding to support research collaboration with Australia’s national science agency, CSIRO The company will work with CSIRO to develop formulations of its small molecule FAK inhibitors that can be...